JP2007500131A5 - - Google Patents

Download PDF

Info

Publication number
JP2007500131A5
JP2007500131A5 JP2006521281A JP2006521281A JP2007500131A5 JP 2007500131 A5 JP2007500131 A5 JP 2007500131A5 JP 2006521281 A JP2006521281 A JP 2006521281A JP 2006521281 A JP2006521281 A JP 2006521281A JP 2007500131 A5 JP2007500131 A5 JP 2007500131A5
Authority
JP
Japan
Prior art keywords
drug
vegf antagonist
packaging
packaging material
antiproliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006521281A
Other languages
English (en)
Japanese (ja)
Other versions
JP5355856B2 (ja
JP2007500131A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/023815 external-priority patent/WO2005011734A2/en
Publication of JP2007500131A publication Critical patent/JP2007500131A/ja
Publication of JP2007500131A5 publication Critical patent/JP2007500131A5/ja
Application granted granted Critical
Publication of JP5355856B2 publication Critical patent/JP5355856B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006521281A 2003-07-25 2004-07-23 Ｖｅｇｆアンタゴニストおよび抗増殖性薬剤の組成物ならびに癌の処置のためのその使用 Expired - Lifetime JP5355856B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49000203P 2003-07-25 2003-07-25
US60/490,002 2003-07-25
US49397103P 2003-08-08 2003-08-08
US60/493,971 2003-08-08
PCT/US2004/023815 WO2005011734A2 (en) 2003-07-25 2004-07-23 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2007500131A JP2007500131A (ja) 2007-01-11
JP2007500131A5 true JP2007500131A5 (cg-RX-API-DMAC7.html) 2010-12-24
JP5355856B2 JP5355856B2 (ja) 2013-11-27

Family

ID=34118812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006521281A Expired - Lifetime JP5355856B2 (ja) 2003-07-25 2004-07-23 Ｖｅｇｆアンタゴニストおよび抗増殖性薬剤の組成物ならびに癌の処置のためのその使用

Country Status (17)

Country Link
US (1) US7354579B2 (cg-RX-API-DMAC7.html)
EP (1) EP1648428A2 (cg-RX-API-DMAC7.html)
JP (1) JP5355856B2 (cg-RX-API-DMAC7.html)
KR (1) KR101175990B1 (cg-RX-API-DMAC7.html)
AR (1) AR046510A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004261165C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0412798A (cg-RX-API-DMAC7.html)
CA (1) CA2529742C (cg-RX-API-DMAC7.html)
IL (1) IL172406A (cg-RX-API-DMAC7.html)
MX (1) MXPA05013642A (cg-RX-API-DMAC7.html)
MY (1) MY149169A (cg-RX-API-DMAC7.html)
NO (1) NO20060924L (cg-RX-API-DMAC7.html)
NZ (1) NZ544570A (cg-RX-API-DMAC7.html)
RU (1) RU2353353C2 (cg-RX-API-DMAC7.html)
TW (1) TWI351953B (cg-RX-API-DMAC7.html)
UY (1) UY28438A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005011734A2 (cg-RX-API-DMAC7.html)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
JP4303105B2 (ja) * 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US20100234570A1 (en) * 2001-06-28 2010-09-16 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CA2519875C (en) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP1853298A2 (en) * 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA3142945A1 (en) * 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
AU2008224929A1 (en) * 2007-03-14 2008-09-18 Mayo Foundation For Medical Education And Research Treating skin cancer
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
LT5610B (lt) 2007-12-17 2009-11-25 Uab Baltec Cnc Technologies, , Kompleksinė sveikatinimo ir sporto įrangos sistema ir jos įgyvendinimo būdas
ES2531322T3 (es) * 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
EP3266453A1 (en) 2008-07-03 2018-01-10 Mayo Foundation for Medical Education and Research Treating cancer
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
HUE048876T2 (hu) 2011-05-09 2020-08-28 Mayo Found Medical Education & Res Rákos megbetegedések kezelése
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
EP3154586B1 (en) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Treating lymphomas
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
CN107073132B (zh) 2014-10-06 2021-08-27 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
EP3414330A4 (en) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109310756B (zh) * 2016-05-13 2022-06-28 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
US11059885B2 (en) 2016-05-13 2021-07-13 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
AU2017324947A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
WO2018160917A1 (en) 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
US20230295266A1 (en) 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
TW202400214A (zh) 2022-03-15 2024-01-01 美商再生元醫藥公司 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案
CN121712520A (zh) 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
WO2025217334A1 (en) 2024-04-09 2025-10-16 Regeneron Pharmaceuticals, Inc. Low concentration vegf receptor fusion protein containing formulations
KR20260096819A (ko) 2024-12-13 2026-06-24 리제너론 파아마슈티컬스, 인크. 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼
WO2026148214A1 (en) 2025-01-02 2026-07-09 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing buffer free formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
CA2519875C (en) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors

Similar Documents

Publication Publication Date Title
JP2005518413A5 (cg-RX-API-DMAC7.html)
GB2419349B (en) One dose at-a-time pill dispenser and container having same
PL400027A1 (pl) Wieloelementowa farmaceutyczna postac dawkowania i sposób jej wytwarzania
IL230815A (en) Dictopyrazine Compounds, Pharmaceuticals Containing Them and Use in the Treatment of T-Mediated Diseases
IL247486B (en) A composition comprising nanoparticles comprising docetaxel, albumin and citrate, uses thereof, a method for it's preparation and a sealed vial and a kit comprising the composition
PL375789A1 (en) Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof
IL161682A0 (en) A medicament container, a medicament dispensing kit for administering medication and a method for packaging the same
AP2006003596A0 (en) A pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases.
PL377656A1 (pl) Ligandy Ó2Ű do różnych zastosowań farmaceutycznych
IL190513A0 (en) Device for the packaging and dispensing of solid shaped bodies, especially oral tablets or/and capsules
PL394600A1 (pl) Związek winyloazacykloalkanowy, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
ITMI20030776A1 (it) Dispositivo per pesare contenitori farmaceutici.
AP2292A (en) Package for pharmaceutical, medical or similar products, particularly pesticides or plant protectionproducts.
AU2003227051A1 (en) Pack for medicine in capsule, pill or similar form
ZA200602788B (en) Amidomethyl-substituted 2-(4-sulfonilamino)-3-hidroxy-3,4-dihydro-2H-chromen-6-YL-derivatives and drugs containing said compounds
DK1530967T3 (da) Blisterpakning og dertil hörende fast dosisform
FR2872493B1 (fr) Materiau d'emballage de sterilisation renforce et emballage le comprenant
FI20021359L (fi) Kuumasaumautuva pakkausmateriaali sekä siitä muodostettu suljettu tuotepakkaus
ITMI20010538V0 (it) Contenitore portatile particolarmente studiato per confezioni tipo "blister",contenenti pastiglie di farmaci, prodotti dolciari, e altri pro
ES1055546Y (es) Contenedor-dosificador para pastillas farmaceuticas.
ZA200501010B (en) BenzoÄBÜchromeno-naphthyridin-7-one and pyranoÄ2'3':7,8ÜquinoÄ2,3-BÜquinoxalin-7-one compounds, process for their preparation and pharmaceutical compositions containing them.
FIU20020497U0 (fi) Jauhemaisen materiaalin annostelu- ja myyntipakkaus
FR2863631B1 (fr) Emballage pour le ramassage des dejections animales.
FR2893923B1 (fr) Paquet d'articles comprenant un flanc couvrant les articles et un film enserrant le tout.
ITVI20030250A1 (it) Macchina perfezionata per l'applicazione di capsule su contenitori, in particolare bottiglie.